Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635
| KDNYDelisted Stock | USD 39.25 0.20 0.51% |
Slightly above 53% of Chinook Therapeutics' investor base is interested to short. The analysis of current outlook of investing in Chinook Therapeutics suggests that many traders are impartial regarding Chinook Therapeutics' prospects. Chinook Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Chinook Therapeutics' earnings reports, geopolitical events, and overall market trends.
Chinook |
SEATTLE, May 05, 2023 -- Chinook Therapeutics, Inc. , a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases,
Read at benzinga.com
 |
Chinook Therapeutics Fundamental Analysis
We analyze Chinook Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Chinook Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Chinook Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Beta
Beta Comparative Analysis
Chinook Therapeutics is currently under evaluation in beta category among its peers. Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Chinook Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Chinook Therapeutics stock to make a market-neutral strategy. Peer analysis of Chinook Therapeutics could also be used in its relative valuation, which is a method of valuing Chinook Therapeutics by comparing valuation metrics with similar companies.
Peers
Chinook Therapeutics Related Equities
| PLRX | Pliant Therapeutics | 2.00 | ||||
| DAWN | Day One | 1.53 | ||||
| VTYX | Ventyx Biosciences | 1.13 | ||||
| TVTX | Travere Therapeutics | 0.59 | ||||
| PCVX | Vaxcyte | 0.38 | ||||
| NUVL | Nuvalent | 0.08 | ||||
| ASND | Ascendis Pharma | 0.18 | ||||
| KALV | Kalvista Pharmaceuticals | 0.30 | ||||
| SWTX | SpringWorks Therapeutics | 0.60 | ||||
| RNA | Avidity Biosciences | 0.69 | ||||
| CRNX | Crinetics Pharmaceuticals | 0.81 | ||||
| ACLX | Arcellx | 1.12 | ||||
| KURA | Kura Oncology | 1.16 | ||||
| RVMD | Revolution Medicines | 1.25 | ||||
| VRDN | Viridian Therapeutics | 1.46 | ||||
| GPCR | Structure Therapeutics | 1.78 |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Other Consideration for investing in Chinook Stock
If you are still planning to invest in Chinook Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Chinook Therapeutics' history and understand the potential risks before investing.
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Stocks Directory Find actively traded stocks across global markets | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities |